Dolphin 'mysteries' to be solved by collecting poo
Conservationists are hoping to learn about a group of bottlenose dolphins that make their home in Welsh waters - by studying their poo.
About 200 bottlenose dolphins are said to live in and around Cardigan Bay and, although they have been studied for several years, experts want to learn more about their relationships, breeding potential and movement patterns.
Analysis of samples will help them to understand what they have been feeding on and where and help build individual profiles for each dolphin.
They will also attempt to match the samples with photo identification records of the dolphins gathered on camera by members of the Wildlife Trust of South and West Wales.
Surfing snake spotted on north Wales beach
Bottlenose dolphins spotted killing dolphin juvenile
'I heard someone say shark and thought it's a hoax'
The trust secured funding for the project from the Welsh government's Nature Networks Fund in collaboration with Aberystwyth University.
The samples will be gathered by net after the dolphins defecate and then analysed by university scientists using techniques to extract detailed data about the animals' diet using environmental DNA (eDNA).
Sarah Perry, the trust's marine conservation and research manager, said she hoped the study would "unravel the mysteries of bottlenose dolphin ecology in Cardigan Bay".
"This project covers an area of research that we have aspired to embark on over the past decade or so and we are excited that it has come to fruition at a time when it is even more important that we build on our knowledge of the species in the waters around us."
Dolphin calf rescued in New Quay
Concerns over sudden drop in sightings of porpoises
Aberystwyth University: Department of Life Sciences
Sea Watch Foundation: Cardiff Bay bottlenose dolphins
Wildlife Trust of South and West Wales
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 days ago
- Yahoo
Dolphin 'mysteries' to be solved by collecting poo
Conservationists are hoping to learn about a group of bottlenose dolphins that make their home in Welsh waters - by studying their poo. About 200 bottlenose dolphins are said to live in and around Cardigan Bay and, although they have been studied for several years, experts want to learn more about their relationships, breeding potential and movement patterns. Analysis of samples will help them to understand what they have been feeding on and where and help build individual profiles for each dolphin. They will also attempt to match the samples with photo identification records of the dolphins gathered on camera by members of the Wildlife Trust of South and West Wales. Surfing snake spotted on north Wales beach Bottlenose dolphins spotted killing dolphin juvenile 'I heard someone say shark and thought it's a hoax' The trust secured funding for the project from the Welsh government's Nature Networks Fund in collaboration with Aberystwyth University. The samples will be gathered by net after the dolphins defecate and then analysed by university scientists using techniques to extract detailed data about the animals' diet using environmental DNA (eDNA). Sarah Perry, the trust's marine conservation and research manager, said she hoped the study would "unravel the mysteries of bottlenose dolphin ecology in Cardigan Bay". "This project covers an area of research that we have aspired to embark on over the past decade or so and we are excited that it has come to fruition at a time when it is even more important that we build on our knowledge of the species in the waters around us." Dolphin calf rescued in New Quay Concerns over sudden drop in sightings of porpoises Aberystwyth University: Department of Life Sciences Sea Watch Foundation: Cardiff Bay bottlenose dolphins Wildlife Trust of South and West Wales
Yahoo
24-04-2025
- Yahoo
A Fingerprint at Stonehenge Changes Everything We Know
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." A chemical fingerprint taken of Stonehenge's Altar Stone reveals that it isn't from Wales, as was previously understood. Instead, researchers believe that the stone came from the Orcadian Basin in Scotland—roughly 466 miles away from the Stonehenge site. While upending previous research, the find also raises questions about how trade networks may have helped transport the stone to the site. Stonehenge offers mysteries aplenty. Just when we think we've solved one, we have to re-solve questions we thought were already answered. Such is the case with the origin story of the Altar Stone—one of the roughly 80-plus stones still on site in southern England. The stones of Stonehenge feature a variety of compositions and originate from a number of potential source locations. Scholars previously believed that they knew most of what there was to be known about the Altar Stone—the largest of the non-sarsen stones on site, which is now partially buried beneath two fallen stones. But researchers led by a team from Curtin University may have just upended that history, writing that a stone long believed to originate from Wales actually hails from Scotland. By studying the age and chemistry of mineral grains within fragments of the six-ton Alter Stone—a thick sandstone block measuring 16 feet by 3 feet in the center of the iconic Wiltshire circle—the team crafted a chemical fingerprint of the stone. That chemical composition matched that of rocks from northeast Scotland, and clearly differentiated it from Welsh bedrock. 'Our analysis found specific mineral grains in the Altar Stone are mostly between 1,000 to 2,000 million years old, while other minerals are around 450 million years old,' Anthony Clarke, lead author and Ph.D. student from the Timescales of Mineral Systems Group at Curtin's School of Earth and Planetary Sciences, said in a statement. 'This provides a distinct chemical fingerprint suggesting the stone came from rocks in the Orcadian Basin, Scotland, at least 750 kilometers [466 miles] away from Stonehenge.' According to English Heritage, the Altar Stone is a large slab of greenish Old Red Sandstone. Recent geological research had pinpointed the source of the stone to the Brecon Beacons area of southeast Wales. But the new study, which was published today in the journal Nature, discounts that reigning theory. Richard Bevins, study co-author and professor at Aberystwyth University, said in a statement that with the chemical fingerprint tracing the iconic rock to Scotland, the hunt for its exact point of origin starts now. Clarke said that the Scottish origins of the stone raise fascinating question regarding how such a massive stone was transported so far during the Neolithic era of roughly 2,600 BC. It must have required, the authors claim, an unexpectedly advanced transport method and complex societal organization. 'Our discovery of the Altar Stone's origins highlights a significant level of societal coordination during the Neolithic period and helps paint a fascinating picture of prehistoric Britain,' Chris Kirkland, study co-author and Curtin professor, said in a statement. 'Transporting such massive cargo overland from Scotland to southern England would have been extremely challenging, indicating a likely marine shipping route along the coast of Britain. This implies long-distance trade networks and a higher level of societal organization than is widely understood to have existed during the Neolithic period in Britain.' You Might Also Like Can Apple Cider Vinegar Lead to Weight Loss? Bobbi Brown Shares Her Top Face-Transforming Makeup Tips for Women Over 50
Yahoo
11-04-2025
- Yahoo
Medical Boost for Young Men as New, Highly Accurate Early Detection Testicular Cancer Test Launched by EDX Medical in UK
CAMBRIDGE, England, April 11, 2025--(BUSINESS WIRE)--The world's most advanced early detection test for testicular cancer – now the most common form of cancer among young men – is being launched in the UK. The non-invasive test has exceptional sensitivity in a broad range of men across ethnicities and ages and also detects cancer recurrences at ultra-high accuracy with 100% sensitivity following treatment and during ongoing surveillance of testicular cancer survivors. There are around 2,500 new cases of testicular cancer in the UK every year and 50,000 survivors of testicular cancer who could benefit from accurate post-treatment monitoring. Notable survivors in the UK who campaign for greater awareness of the disease include actor Jack James Ryan, formerly of Coronation Street, radio presenter Chris Stark and former Welsh international footballer, John Hartson. The test is being launched in the UK by EDX Medical, a Cambridge-based company which specialises in developing and supplying digitally enhanced diagnostic tools for cancer, cardiovascular and infectious diseases. April is Testicular Cancer Awareness Month, and many cancer charities and patient advocacy groups aim to highlight the benefits of early detection. Survival rates for testicular cancer are in excess of 90% if the disease is identified and treated early. The EDX Medical test ("TC100") involves the taking of a simple blood sample which is sent to EDX Medical for laboratory analysis. The blood sample can be taken easily by a health professional. Multiple specific tumour biomarkers are analysed and, using a proprietary AI-powered algorithm, a detailed report is prepared for clinicians to help determine the presence or absence of disease and to help guide treatment if required. Over 30 clinical study reports have confirmed the accuracy and potential clinical usefulness of the test biomarkers, encompassing its use in primary diagnosis, early detection, metastatic disease and recurrence of both seminoma and non-seminoma testicular cancer. Combining proprietary M371 micro-RNA biomarker analysis with the classic three serum biomarkers AFP - Alpha-fetoprotein, HCG - Human Chorionic Gonadotrophin and LDH - Lactate Dehydrogenase, using a unique algorithm, the new "TC100" assay provides exceptional accuracy and sets a new standard for testicular cancer testing. The TC100 test reports on the three tumour biomarkers currently included in the NHS testicular cancer treatment pathway as part of the analysis and for ease of reference. The test provides up to 99% sensitivity and 96% specificity in primary diagnosis and 100% in monitoring recurrence. The test, which is to be used by health professionals as an aid to their clinical diagnosis, will be available to all private sector and public healthcare providers within several weeks. Professor Sir Chris Evans, OBE, founder of EDX Medical Group plc, commented: "Testicular cancer is a nightmarish thought for young men and there has been a lack of awareness over what to do and an unwillingness to get tested. "We are delighted to launch in the UK now the best test ever made. Given that this disease affects boys from 15 years old to men in their early forties, there are many who could benefit from testing in terms of reassurance and this particularly applies to people who have been diagnosed and need checked on a regular basis." Jack James Ryan, who campaigns on behalf of the Teenage Cancer Trust, commented: "There's still such a huge stigma around testicular cancer especially with the process of getting physically checked in the private parts and that needs to change. Even after your initial check you need to be scanned if there are concerns, so you still don't know the outcome of what you have been worried about. "Being able to give a simple blood sample that is then analysed and that tells you with a high degree of certainty whether you have this cancer or not - as opposed to the physical examinations - would eliminate the awkward and uncomfortable physical process that so many young men shy away from. By making the process of detection easier and more casual - and very accurate - it'll convince more young men to get tested quicker and in turn will save lives. This really is a game changer!" Dr Karen Robb, Director of Programme Implementation for Cancer at Movember, the leading men's health charity, commented: "This test is a great step and a part of the bigger picture to improve early diagnosis. During Testicular Cancer Awareness Month, Movember is reminding young men to 'Know Thy Nuts' — that means getting familiar with what's normal for your body and speaking up if something doesn't feel right. Early detection starts with awareness, and knowing your risks can save your life." Leading Michelin-starred chef and restaurateur, Andreas Antona, was diagnosed with testicular cancer in 2012 and believes early testing will be life-saving for young men. He said: "We all say that if we knew then what we know now, we'd have made different decisions and how true that is when it comes to cancer. Early detection will undoubtedly save young men's lives and prevent much unnecessary suffering by earlier intervention. This type of testing can also give great peace of mind and help someone live life without worrying about cancer all the time." Dr Mike Hudson, CEO, EDX Medical, said: "The highly sensitive "TC100" testicular cancer test will help doctors to accurately identify testicular cancer early and better manage the safe and effective care of their patients. The quick confirmation of early signs of disease, the absence of cancer following treatment and to monitor any signs of recurrence during surveillance will help minimise scans, biopsies and the unnecessary use of toxic chemotherapy, significantly improving quality of life for patients." Notes for Editors: About EDX Medical Group EDX Medical Group plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX). EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson. By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically-based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally. EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services. EDX Medical conducts product development, validation and distribution to ISO 13485 and provides PCR and genomic sequencing services accredited to ISO 15189 by the United Kingdom Accreditation Service (UKAS). View source version on Contacts Media contacts: Media House International Ramsay Smith +44 (0)7788 414856 ramsay@ Gary McQueen + 44 (0)7834 694609 gary@ Sign in to access your portfolio
